Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
about
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerMolecular alterations and biomarkers in colorectal cancerEGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Where now for anti-EGF receptor therapies in colorectal cancer?Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR statusPanitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.Alteration of EGFR spatiotemporal dynamics suppresses signal transduction.Colorectal cancer molecular biology moves into clinical practice.EGFR Signaling in Colorectal Carcinoma.Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotypingEGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes.High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx™: a study of diagnostic accuracyEGFR status in oral squamous cell carcinoma: comparing immunohistochemistry, FISH and CISH detection in a case series studyGenetic alterations of HER genes in chromophobe renal cell carcinomaPathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients.A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.Current role of antibody therapy in patients with metastatic colorectal cancer.Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system.Frequent mutations of the CA simple sequence repeat in intron 1 of EGFR in mismatch repair-deficient colorectal cancers.A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer.Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expressionColorectal cancer in review: the role of the EGFR pathway.The level of epidermal growth factor receptors expression is correlated with the advancement of colorectal adenoma: validation of a surface biomarker.Genetic Interactions of STAT3 and Anticancer Drug Development.Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
P2860
Q24675853-003BBAD2-DE42-4D87-9A35-0D6607D3B2F4Q26751344-2ECC5FF5-50F4-4BF2-9FB4-7B049E5160BFQ26771952-99D1CE40-3BA8-4C46-A6FE-EB78B4B68E6FQ26862317-C275560F-BB26-4A1B-9D60-003ADD4496F7Q27852970-EDD9016D-DB78-4624-8D49-D13DA5B6A2C5Q31038305-E900A8A4-3F41-417F-BF22-0B10E7DC3CE5Q33313648-9D6D4C32-16F7-4C2D-ABFE-26E77F70CD04Q33359798-760B4D63-126F-4868-904B-A911D5788319Q33497634-47D71DC3-B272-4A30-B044-94525313A968Q33620091-C0387949-4459-48DA-AEB9-6196E1B85B66Q34239801-D4FD656C-B26B-487E-A742-16132F485F1AQ34250130-CF4691FB-2A24-4780-AE2C-A551F1B08F94Q34326437-645A3B7E-4442-4D2E-8105-1D0AAA880902Q34425013-93EFF45E-3C51-4F98-82E6-82BC6611ABCEQ34627605-9E299AD2-95C6-42D4-89BA-A4EC802E385BQ34760933-58F8EF6C-1620-4F07-BE36-D95FC6128815Q35125640-35900684-47BB-436E-A73C-82917F1C9C1AQ35710375-3EF4489A-D4C7-4BED-A1E5-3B4C2D1A9640Q36449863-8AC490FB-030F-4019-8D8D-3DB3BBA5F4FFQ36584164-8F48D6FA-17C3-41CA-8947-99E7479D7DEFQ36640781-503A5276-0CCC-4A1E-8BC5-0307FC76E27AQ36671291-EB15BCD7-31C5-49DB-9F60-AC9483BCF336Q36728796-6530A266-284C-4262-B047-1B641ECB7371Q36810255-3CD5E07C-438A-489C-A06C-5489ABA6ADBFQ36832121-8B9C962E-056B-48A1-AC4B-210C35CBAADEQ36920799-B3E4320C-CB49-4D2B-BFCB-92AA3A0608FBQ37043503-7C49C841-AC02-42AB-99A1-6773EED0DB39Q37059520-7EB4891E-1C0A-45AB-A938-EAD4A11498D6Q37209926-216A6A1C-22F5-4A85-B9F7-7E5F973A73F2Q37222532-65FA54DE-C0B0-4EB3-88BD-5B169F0A8277Q37240838-2F8141ED-24BB-41EA-A771-7C8F4181F21FQ37301478-78520C12-2BEF-4680-B888-67098931E786Q37321897-9A2D6947-B3C9-456A-A7B9-3EE00104C1AFQ37372466-CC4EFD78-9279-4F0C-86D9-3BEAEFEA15D3Q37378581-E2CBE703-66BE-4F3C-9CDD-0715147487B6Q37448192-056B46B9-C47D-47E8-B457-BD9237599DEDQ37679938-9515BC2A-5E06-43A5-A5D9-CC41E647D3FEQ37725469-D26F397B-D2A8-4587-9069-FDA0DA1CA5D3Q38198930-0B08D09C-6E6E-44A6-8201-BE6CCE58C43EQ38463163-76AE5BE7-B493-4F02-B810-F5D349A543CD
P2860
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Epidermal growth factor recept ...... c in situ hybridization study.
@ast
Epidermal growth factor recept ...... c in situ hybridization study.
@en
Epidermal growth factor recept ...... c in situ hybridization study.
@nl
type
label
Epidermal growth factor recept ...... c in situ hybridization study.
@ast
Epidermal growth factor recept ...... c in situ hybridization study.
@en
Epidermal growth factor recept ...... c in situ hybridization study.
@nl
prefLabel
Epidermal growth factor recept ...... c in situ hybridization study.
@ast
Epidermal growth factor recept ...... c in situ hybridization study.
@en
Epidermal growth factor recept ...... c in situ hybridization study.
@nl
P2093
P2860
P1433
P1476
Epidermal growth factor recept ...... c in situ hybridization study.
@en
P2093
Allan R Li
Beiyun Chen
David S Klimstra
Jinru Shia
Ki Young Chung
Leonard Saltz
Muzaffar Akram
Philip B Paty
P2860
P2888
P304
P356
10.1038/MODPATHOL.3800417
P577
2005-10-01T00:00:00Z
P5875
P6179
1004130509